SYS-CON MEDIA Authors: Jason Bloomberg, Kevin Benedict, David H Deans, RealWire News Distribution, Gilad Parann-Nissany

News Feed Item

Atonomics Achieves Significant Milestone Related to Performance Data for Troponin I Assay Triggering Scheduled Payments From Beckman Coulter

COPENHAGEN, Denmark, November 26, 2012 /PRNewswire/ --

Atonomics A/S announced today that it has achieved an important milestone related to a defined set of performance criteria for a Troponin I assay on the new Atolyzer® system.

     (Logo: http://photos.prnewswire.com/prnh/20121126/578019 )

Since entering an equity investment agreement with Beckman Coulter in May of last year to advance the Atolyzer® within cardiac testing, the company has worked diligently to deliver relevant Troponin I performance data.

"We are pleased to achieve this milestone," said Thomas Warthoe, Atonomics' CEO. "Troponin I is one of the most difficult assays to transfer to a near-patient system and still deliver data that are comparable to what the physicians get from the central laboratory; we believe the Atolyzer® has the potential to allow physicians in the future to continue to safely implement data from a near patient system."

"We expect that this recent and significant achievement will generate appropriate interest from Industry in order to reach the full potential of the Atolyzer® platform," said Ashok Dhanrajgir, Chairman of Atonomics board of directors and senior partner with Inventages Venture Capital

Atonomics' majority shareholders are Inventages Venture Capital, Sunstone Capital, NeuroSearch A/S,  and Beckman Coulter.

About Atonomics

Atonomics is an emerging technology company based in Copenhagen, Denmark, that designs and manufactures the innovative Atolyzer® system for near-patient testing in hospitals, clinics, physician offices  and patient monitoring. Atonomics is pursuing a strategy to partner with leading players in the industry to bring a new dimension of quality to the point-of-care market. The Atolyzer® system is a platform for immuno-diagnostic and molecular diagnostic testing. The Atolyzer® is designed for simplicity and ease of use while preserving performance and safety. The stand-alone device is operated with a single touch by any health worker and can be positioned in any location throughout the hospital, clinic or office where large systems cannot operate, representing true near-patient testing.

Contacts:

Atonomics
Thomas Warthoe, CEO
Phone: +45-70271330
Email: [email protected] 
Web: http://www.atonomics.com

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.